ClinicalTrials.gg
CompletedNCT05372588COVID-19Updated Apr 23, 2024

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

A Phase 3 interventional study of NVX-CoV2515 and NVX-Cov2373 in COVID-19 and SARS CoV 2 Infection, sponsored by Novavax. Completed at 19 sites in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,340
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
7th of 18
1,340 · median 997
Started
2022
with 4 others
Phase 3
7 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 7th largest by enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 8th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccines (SARS-CoV-2 rS) adjuvanted with Matrix-M™ adjuvant (NVX-CoV2515 [BA.1] and NVX-CoV2540 [BA.5]) and bivalent (NVX-CoV2373 [prototype] + Omicron subvariant) SARS-CoV-2 rS vaccines (NVX-CoV2373 + NVX CoV2515 and NVX CoV2373 + NVX CoV2540) in previously vaccinated adults 18 years of age and older.

03

Conditions studied

  • COVID-19
  • SARS CoV 2 Infection

Keywords

  • Coronavirus
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part 1

Inclusion Criteria:

To be included in this study, each individual must satisfy all the following criteria:

  1. Adults ≥ 18 and ≤ 64 years of age at screening.
  2. Willing and able to give prior to study enrollment and to comply with study procedures.
  3. Female participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of listed below from ≥ 28 days prior to and through the end of the study.
  4. Is medically stable, as determined by the investigator (based on a review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the vaccination.
  5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
  6. Have previously received 2 doses of the Moderna and/or Pfizer-BioNTech COVID-19 prototype vaccines with the last dose having been given ≥ 180 days prior to study vaccination or 3 doses of the Moderna and/or Pfizer-BioNTech COVID-19 prototype vaccines with the last dose having been given ≥ 90 days previously prior to the study vaccination.

Exclusion Criteria:

If an individual meets any of the following criteria, he or she is ineligible for this study:

  1. Received COVID-19 vaccines other than Moderna and/or Pfizer-BioNTech in the past, inclusive of clinical trial COVID- 19 vaccines.
  2. Participation in research involving receipt of products (drug/biologic/device) within 90 days prior to study vaccination.
  3. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccination which may be received > 14 days prior to study vaccination, or rabies vaccine which may be given if medically indicated.
  4. Any known allergies to products contained in the investigational product.
  5. Any history of anaphylaxis to any prior vaccine.
  6. or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy.
  7. Chronic administration (defined as > 14 continuous days) of , systemic , or other immune-modifying drugs within 90 days prior to study vaccination.
  8. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to the first study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  9. Active cancer () on therapy within 3 years prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  10. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of the study.
  11. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  12. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  13. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization (CRO), and study site personnel involved in the conduct or planning of the study).

Part 2

Inclusion Criteria:

To be included in this study, each individual must satisfy all of the following criteria:

  1. Adults and adolescents ≥ 18 years of age at screening.
  2. Willing and able to give informed consent prior to study enrollment and to comply with study procedures.
  3. Female participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study OR agree to consistently use a medically acceptable method of contraception listed below from ≥ 28 days prior to enrollment and through the end of the study.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the first vaccination.
  5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for the duration of the study.
  6. Have previously received ≥ 3 doses of the Moderna and/or Pfizer-BioNTech monovalent and/or bivalent COVID-19 vaccines with the last dose having been given ≥ 90 days previously prior to first study booster.

Exclusion Criteria:

If an individual meets any of the following criteria, he or she is ineligible for this study:

  1. Received COVID-19 vaccines other than Moderna and/or Pfizer-BioNTech in the past, inclusive of clinical trial COVID-19 vaccines.
  2. Participation in research involving receipt of investigational products (drug/biologic/device) within 90 days prior to first study vaccination.
  3. Received any vaccine ≤ 90 days prior to study vaccination, except for influenza vaccination which may be received > 14 days prior to first study vaccination, or rabies vaccine which may be given if medically indicated.
  4. Any known allergies to products contained in the investigational product.
  5. Any history of anaphylaxis to any prior vaccine.
  6. Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy.
  7. Chronic administration (defined as > 14 continuous days) of immunosuppressant, systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to first study vaccination.
  8. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to first study vaccination, except for rabies immunoglobulin which may be given if medically indicated.
  9. Active cancer (malignancy) on therapy within 3 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  10. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study.
  11. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to the first study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance.
  12. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
  13. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization [CRO], and study site personnel involved in the conduct or planning of the study).
  14. Participants with a history of myocarditis or pericarditis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,340 participants (actual)

Study arms

  • Experimental
    Group A (NVX-CoV2515 )

    1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.

    Drug: NVX-CoV2515

  • Experimental
    Group B (NVX-CoV2373 )

    1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.

    Drug: NVX-Cov2373

  • Experimental
    Group C (NVX-CoV2515 )

    1 intramuscular (IM) injection of NVX-CoV2515 of 0.5 mL injection volume on Day 0.

    Drug: NVX-CoV2515

  • Experimental
    Group D (NVX-CoV2373)

    1 intramuscular (IM) injection of NVX-CoV2373 of 0.5 mL injection volume on Day 0.

    Drug: NVX-Cov2373

  • Experimental
    Group E (BA.1 Bivalent Vaccine)

    1 intramuscular (IM) injection of Bivalent Vaccine (NVX-CoV2373 + NVX-CoV2515) of 0.5 mL injection volume on Day 0.

    Drug: NVX-CoV2373 + NVX-CoV2515

  • Experimental
    Group F (NVX-CoV2540)

    2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.

    Drug: NVX-CoV2540

  • Experimental
    Group G (NVX-CoV2373)

    2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.

    Drug: NVX-Cov2373

  • Experimental
    Group H (NVX-CoV2373 + NVX-CoV2540)

    2 intramuscular (IM) injections of NVX-CoV2373 of 0.5 mL injection volume on Day 0 and on Day 90.

    Drug: NVX-CoV2373 + NVX-CoV2540

Interventions

  • DrugNVX-CoV2515

    Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).

    Also known as: Omicron BA.1 SARS-CoV-2 rS /Matrix-M Adjuvant

  • Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).

    Also known as: SARS-CoV-2 rS/Matrix-M Adjuvant

  • DrugNVX-CoV2373 + NVX-CoV2515

    Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.

    Also known as: Prototype/BA.1 Bivalent Vaccine

  • DrugNVX-CoV2540

    Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).

    Also known as: Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant

  • DrugNVX-CoV2373 + NVX-CoV2540

    Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.

    Also known as: Prototype/BA.5 Bivalent Vaccine

06

What researchers measure

Primary outcomes

  1. Part 1: MN50 geometric mean titers (GMTs) to the Omicron BA.1 subvariant expressed as GMTs

    Microneutralization \[MN\] geometric mean titers (GMTs) with an inhibitory concentration of 50% (MN50) to the Omicron BA.1 subvariant, assessed at Day 14 following initial study vaccination and analyzed by previous vaccine combination received.

    Time frame: Day 14

  2. Part 1: MN50 titer concentrations to the Omicron BA.1 subvariant vaccine expressed as seroresponse rates (SRRs)

    Seroresponse rates (SRRs) (proportion of participants who achieve ≥ 4-fold increase from baseline \[Day 0\]) in MN50 titer concentrations to the Omicron BA.1 subvariant, assessed at Day 14 following initial study vaccination and analyzed by previous vaccine combination received.

    Time frame: Day 14

  3. Part 2: Neutralizing Antibody (NAb) GMTs to the Omicron BA.5 subvariant expressed as GMTs

    Neutralizing antibody (NAb) GMTs to the Omicron BA.5 subvariant, assessed at Day 28 following initial study vaccination.

    Time frame: Day 28

  4. Part 2: Neutralizing Antibody (NAb) titers to the Omicron BA.5 subvariant expressed as SRRs

    SRRs in NAb titer concentrations to the Omicron BA.5 subvariant, assessed at Day 28 following initial study vaccination

    Time frame: Day 28

  5. Part 2: Neutralizing Antibody (NAb) titers to the ancestral (Wuhan) strain expressed as GMTs

    NAb GMTs to the ancestral (Wuhan) strain, assessed at Day 28 following initial study vaccination.

    Time frame: Day 28

Secondary outcomes

  1. Part 1: MN50 geometric mean titers (GMTs) to the ancestral (Wuhan),and Omicron BA.1 viruses expressed as GMT

    MN50 GMTs to the ancestral (Wuhan), and Omicron BA.1 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  2. Part 1: MN50 titer concentrations to the ancestral (Wuhan), and Omicron BA.1 viruses expressed as GMFR

    MN50 geometric mean fold rise (GMFR) to the ancestral (Wuhan), and Omicron BA.1 viruses at relevant time points (Days 7, 14, 28, and 240) from baseline (Day 0) and analyzed by previous vaccine combination received.

    Time frame: Day 7 to Day 240

  3. Part 1: MN50 titer concentrations to the ancestral (Wuhan), and Omicron BA.1 viruses expressed as SRRs

    SRRs in MN50 titer concentrations to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 7 to Day 240

  4. Part 1: Immunoglobulin G (IgG) antibody levels to the ancestral (Wuhan), Omicron BA.1 and Omicron BA.5 viruses expressed as GMT

    Immunoglobulin G (IgG) antibody levels to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combinations received.

    Time frame: Day 0 to Day 240

  5. Part 1:IgG antibody levels to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses expressed as GMFR

    IgG antibody levels to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  6. Part 1: IgG antibody levels to the ancestral (Wuhan), Omicron BA.1 and Omicron BA.5 viruses expressed as SRRs

    IgG antibody levels to the ancestral (Wuhan) and Omicron BA.5 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  7. Part 1: Human angiotensin-converting enzyme 2 (hACE2) receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses expressed as GMTs

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  8. Part 1: hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses expressed as GMFR

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 viruses at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received. Derived/calculated endpoints based on these data will include GMFR.

    Time frame: Day 0 to Day 240

  9. Part 1: hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as SRR

    hACE2 receptor binding inhibition assay to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received. Derived/calculated endpoints based on these data will include SRRs.

    Time frame: Day 0 to Day 240

  10. Part 1: MN50 GMTs to the to the ancestral (Wuhan) virus expressed as GMT

    MN50 GMTs to the ancestral (Wuhan) virus, assessed at Day 14 following initial study vaccination and analyzed by previous vaccine combination received.

    Time frame: Day 14

  11. Part 1: MN50 GMTs to the to the ancestral (Wuhan) virus expressed as GMFR

    MN50 GMFRs to the ancestral (Wuhan) virus at Day 14, from baseline (Day 0) and analyzed by previous vaccine combination received.

    Time frame: Day 14

  12. Part 1: SRRs in MN50 titer concentrations to the ancestral (Wuhan) virus expressed as SRRs

    SRR in MN50 titer concentrations to the ancestral (Wuhan) virus, assessed at Day 14 following initial study vaccination.

    Time frame: Day 14

  13. Part 1: MN50 GMTs to the Omicron BA.1 subvariant virus expressed as GMT

    MN50 GMTs to the Omicron BA.1 subvariant virus, assessed at Day 14 following initial study vaccination and analyzed by previous vaccine combination received.

    Time frame: Day 14

  14. Part 1: MN50 GMTs to the Omicron BA.1 subvariant virus expressed as GMFR

    MN50 GMFRs to the Omicron BA.1 subvariant virus at Day 14, from baseline (Day 0) and analyzed by previous vaccine combination received.

    Time frame: Day 14

  15. Part 1: MN50 GMTs to the Omicron BA.1 subvariant virus expressed as SRR

    SRR in MN50 titer concentrations to the Omicron BA.1 variant virus, assessed at Day 14 following initial study vaccination.

    Time frame: Day 14

  16. Part 1 and Part 2: Incidence of solicited local and systemic Adverse Events (AEs)

    Incidence, duration, and severity of solicited local and systemic AEs for 7 days following vaccination.

    Time frame: Day 7

  17. Part 1 and Part 2 : Incidence of unsolicited AEs

    Incidence, duration, severity, and relationship of unsolicited AEs through 28 days after vaccination.

    Time frame: Day 28

  18. Part 1 and Part 2 :Incidence and relationship of Medically Attended Adverse Event(s) (MAAEs), Adverse event(s) of Special Interest (AESIs), and Serious Adverse Event(s) (SAEs)

    Incidence and relationship of MAAEs, AESIs (predefined list), and SAEs throughout the study

    Time frame: Day 0 to Day 270

  19. Part 1: IgG Geometric Mean Concentrations (GMCs) to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as GMFR

    IgG GMCs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  20. Part 1: IgG GMCs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as SRR

    IgG GMCs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  21. Part 1: GMTs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as SRR

    GMTs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  22. Part 1: GMTs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins expressed as GMFR

    GMTs to the ancestral (Wuhan), Omicron BA.1, and Omicron BA.5 S proteins at relevant time points (Days 0, 7, 14, 28, and 240) and analyzed by previous vaccine combination received.

    Time frame: Day 0 to Day 240

  23. Part 2: Neutralizing Antibody (NAb) titers to the ancestral (Wuhan) and Omicron BA.5 strains expressed as GMTs

    NAb GMTs to the ancestral (Wuhan) and Omicron BA.5 strains at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  24. Part 2: Neutralizing Antibody (NAb) titers to the ancestral (Wuhan) and Omicron BA.5 strains expressed as GMFRs

    NAb GMFR to the ancestral (Wuhan), and Omicron BA.5 strains at relevant time points (Days 14, 28, 104, 118, and 270) from baseline (Day 0 or Day 90) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  25. Part 2: Neutralizing Antibody (NAb) titers to the ancestral (Wuhan) and Omicron BA.5 strains expressed as SRRs

    SRRs in NAb titers to the ancestral (Wuhan) and Omicron BA.5 strains at relevant time points (Days 14, 28, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  26. Part 2: IgG GMEUs antibody levels to the ancestral (Wuhan) and Omicron BA.5 S proteins expressed as GMTs

    IgG GMEUs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  27. Part 2: IgG GMEUs antibody levels to the ancestral (Wuhan) and Omicron BA.5 S proteins expressed as GMFRs

    IgG GMEUs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  28. Part 2: IgG GMEUs antibody levels to the ancestral (Wuhan) and Omicron BA.5 S proteins expressed as SRRs

    IgG GMEUs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  29. Part 2:hACE2 receptor binding inhibition assay to the ancestral (Wuhan),and Omicron BA.5 S proteins expressed as GMTs

    hACE2 receptor binding inhibition assay GMTs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  30. Part 2:hACE2 receptor binding inhibition assay to the ancestral (Wuhan), and Omicron BA.5 S proteins expressed as GMFRs

    hACE2 receptor binding inhibition assay GMTs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

  31. Part 2:hACE2 receptor binding inhibition assay to the ancestral (Wuhan), and Omicron BA.5 S proteins expressed as SRRs

    hACE2 receptor binding inhibition assay GMTs to the ancestral (Wuhan) and Omicron BA.5 S proteins at relevant time points (Days 0, 14, 28, 90, 104, 118, and 270) and analyzed by age group (overall, 18 to 54, and ≥ 55 years of age).

    Time frame: Day 0 to Day 270

07

Study locations

19 sites
  • Paratus Clinical Research Canberra
    Bruce, Australian Capital Territory 2617, Australia
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • Northern Beaches Clinical Research
    Brookvale, New South Wales 2100, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, New South Wales 2291, Australia
  • Australian Clinical Research Network (ACRN)
    Maroubra, New South Wales 2035, Australia
  • AIM Centre (Hunter Diabetes Centre)
    Merewether, New South Wales 2291, Australia
  • Novatrials
    Newcastle, New South Wales 2289, Australia
  • Holdsworth House Medical Practice
    Sydney, New South Whales 2010, Australia
  • Paratus Clinical Research Brisbane
    Albion, Queensland 4010, Australia
  • Core Research Group Pty Ltd
    Milton, Queensland 4064, Australia
  • Griffith University Clinical Trial Unit
    Southport, Queensland 4222, Australia
  • Data Health Australia PTY Ltd t/a Austrials
    Taringa, Queensland 4068, Australia
  • AusTrials Wellers Hill
    Wellers Hill, Queensland 4121, Australia
  • Clinical Medical and Analytical Excellence (CMAX)
    Adelaide, South Australia 5000, Australia
  • Eastern Health-Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • University Hospital Geelong-Barwon Health
    Geelong, Victoria 3220, Australia
  • Monash Health -Monash Medical Centre
    Melbourne, Victoria 3168, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2022, 1 month.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 12, 2022
StartActual
May 25, 2022
Primary completionActual
Jul 17, 2022
CompletionActual
Apr 7, 2024
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05372588
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
May 12, 2022
Start date
May 25, 2022
Primary completion
Jul 17, 2022
Completion
Apr 7, 2024
Last update
Apr 23, 2024

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion